Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102310 · ClinicalTrials.gov registry record · Phase 2
YM443 in Subjects With Functional Dyspepsia
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 416
- Enrollment target
NCT00102310 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 416 participants.
The verdict
NCT00102310, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 416 participants
- Enrollment target
Study Summary
The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.
Interventions
- DRUG YM443
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2004-03-10 |
| Est. Completion | 2006-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102310
The ClinicalTrials.gov registry entry for NCT00102310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which YM443 is the first listed.
NCT00102310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102310 about?
NCT00102310 is a clinical study titled "YM443 in Subjects With Functional Dyspepsia". The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.
What is the current status of trial NCT00102310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 416 participants. The study started on 2004-03-10. Estimated completion is 2006-03-11.
What interventions are being tested in trial NCT00102310?
The interventions under investigation include: YM443 (DRUG).
Who is sponsoring clinical trial NCT00102310?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.